Novo Nordisk Offers Discounted Subscription Plan For US Patients Using Wegovy

Novo Nordisk (NVO) has announced a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, in a bid to compete more effectively with Eli Lilly.

Patients can save up to $600 per year on Wegovy pills and up to $1,200 per year on Wegovy injections with a 12-month subscription, Novo said. The plan, available through telehealth platforms like Ro, WeightWatchers, and LifeMD, allows eligible patients to choose three-, six-, or 12-month subscriptions, with bigger discounts for longer commitments.

Hims & Hers, Sesame, and other telehealth companies are expected to offer discounts soon.

Monthly prices for Wegovy injections range from $329 for three months to $249 for a year-long plan, compared to the usual $349. The pill version is priced between $ 249 and $ 289 per month. Eli Lilly's self-pay pricing for Zepbound starts at $299 per month for the 2.5 mg dose, rising to $399 for 5 mg, $449 for 7.5 mg, and higher doses.

NVO shares edged 0.3% lower in pre-market trading on Tuesday.

Get updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.